Nivolumab/pembrolizumab

Nivolumab/pembrolizumab Reactions 1704, p284 - 2 Jun 2018 Pancreatitis and sarcoidosis : 3 case reports In a retrospective study of 53 patients, three patients [age and sex not stated], were described, who developed pancreatitis (2 patients) and sarcoidosis (1 patient) following treatment with nivolumab or pembrolizumab [routes and dosages not stated, not all durations of treatments to reactions onsets and outcomes stated]. All the three patients had cancer. Among these three patients, one patient received an injection of nivolumab and developed sarcoidosis seven weeks later. The patient’s sarcoidosis improved after corticosteroid therapy. Of the remaining two, one patient developed pancreatitis seven weeks after receiving first administration of nivolumab. The third patient developed pancreatitis following administration of pembrolizumab. Author comment: "[P]atients included in the present study had lipase increase related to anti-PD1 treatments. Two of the seven patients had pancreatitis imaging features, with abnormalities on CT scan. Programmed death receptor-1 blocking antibodies (anti-PD1) are a new standard of care in many cancer types. Patients benefit from improved survival but have the risk of immune-related adverse events (irAE) [Sarcoidosis-like syndrome]." Mekki A, et al. Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1. European Journal of Cancer 96: 91-104, Jun 2018. Available from: URL: http://doi.org/10.1016/j.ejca.2018.03.006 - France 803322916 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Nivolumab/pembrolizumab

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018
Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/nivolumab-pembrolizumab-zSZcqBEtU9
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-018-46927-4
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p284 - 2 Jun 2018 Pancreatitis and sarcoidosis : 3 case reports In a retrospective study of 53 patients, three patients [age and sex not stated], were described, who developed pancreatitis (2 patients) and sarcoidosis (1 patient) following treatment with nivolumab or pembrolizumab [routes and dosages not stated, not all durations of treatments to reactions onsets and outcomes stated]. All the three patients had cancer. Among these three patients, one patient received an injection of nivolumab and developed sarcoidosis seven weeks later. The patient’s sarcoidosis improved after corticosteroid therapy. Of the remaining two, one patient developed pancreatitis seven weeks after receiving first administration of nivolumab. The third patient developed pancreatitis following administration of pembrolizumab. Author comment: "[P]atients included in the present study had lipase increase related to anti-PD1 treatments. Two of the seven patients had pancreatitis imaging features, with abnormalities on CT scan. Programmed death receptor-1 blocking antibodies (anti-PD1) are a new standard of care in many cancer types. Patients benefit from improved survival but have the risk of immune-related adverse events (irAE) [Sarcoidosis-like syndrome]." Mekki A, et al. Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1. European Journal of Cancer 96: 91-104, Jun 2018. Available from: URL: http://doi.org/10.1016/j.ejca.2018.03.006 - France 803322916 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704

Journal

Reactions WeeklySpringer Journals

Published: Jun 2, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off